Correct Answer: C. Obstructive disease
The FEV1/FVC ratio is the single most discriminating spirometric parameter for obstructive versus restrictive disease. In obstructive airway disease (asthma, COPD, bronchiectasis), the hallmark is disproportionate reduction in FEV1 relative to FVC. This occurs because airway obstruction causes air trapping and dynamic compression of small airways during forced expiration, preventing complete emptying of the lungs. FEV1 drops dramatically (e.g., 40–50% predicted), while FVC remains relatively preserved or only mildly reduced. Thus the ratio falls below 0.70 (or 70%), which is the diagnostic threshold per GOLD criteria and Indian respiratory guidelines. In India, COPD (from smoking and biomass exposure) and asthma are the most common obstructive diseases encountered. The mechanism is purely mechanical obstruction of airflow, not loss of lung parenchyma. This ratio is far more sensitive and specific for obstruction than absolute FEV1 alone, which can be low in both restrictive and obstructive disease.
Why the other options are wrong
A. Restrictive disease — In restrictive disease (pulmonary fibrosis, chest wall disease, neuromuscular weakness), both FEV1 and FVC are reduced proportionally because the lungs cannot expand adequately. The FEV1/FVC ratio remains normal or even elevated (>0.70) because airway obstruction is absent—the problem is parenchymal loss or mechanical restriction. This is the key discriminator: restrictive disease preserves the ratio while reducing absolute volumes. B. Normal lung function — Normal spirometry shows FEV1/FVC ≥0.70 with FEV1 and FVC both ≥80% predicted. A reduced FEV1/FVC ratio by definition indicates abnormal lung function. This option confuses students who forget that the ratio itself is the diagnostic criterion—a low ratio is pathological, not normal. D. Interstitial lung disease — Interstitial lung disease (IPF, sarcoidosis, hypersensitivity pneumonitis) is a restrictive pattern, not obstructive. Both FEV1 and FVC are reduced proportionally, keeping the FEV1/FVC ratio normal or high. The reduced ratio is not seen in ILD unless concurrent obstruction (e.g., smoking-related changes) is present. This option traps students who conflate 'reduced FEV1' with obstruction.
High-Yield Facts
- FEV1/FVC <0.70 is diagnostic of obstructive airway disease (GOLD criterion); ratio ≥0.70 rules out obstruction.
- Air trapping and dynamic airway compression during forced expiration cause disproportionate FEV1 reduction in obstruction; FVC is relatively spared.
- Restrictive disease preserves FEV1/FVC ratio (often >0.70) because both FEV1 and FVC fall proportionally due to parenchymal loss or mechanical restriction.
- COPD and asthma are the most common obstructive diseases in India; biomass exposure and smoking are major risk factors.
- FEV1 alone is not diagnostic—it can be low in both restrictive and obstructive disease; the ratio is the discriminator.
Mnemonics
OBstructive = disproportionate FEV1 drop Obstructive → FEV1 falls MORE than FVC → ratio drops. Restrictive → both fall equally → ratio stays normal. Use when comparing spirometry patterns. RATIO rule: <0.70 = Obstruction FEV1/FVC <0.70 (or <70%) = Obstruction. ≥0.70 = Restrictive or Normal. Memorize 0.70 as the magic cutoff for every spirometry question.
NBE Trap
NBE often pairs "reduced FEV1" with restrictive disease to trap students who forget that FEV1 can be low in both patterns—the ratio, not the absolute value, distinguishes obstruction from restriction. Students who only remember "low FEV1 = bad lungs" may incorrectly choose restrictive disease.</trap> <parameter name="textbookRef">Harrison Ch. 246 (Pulmonary Function Testing); Robbins Ch. 15 (Obstructive Airway Disease); KD Tripathi Ch. 48 (Respiratory Pharmacology)</textbookRef> <parameter name="clinicalPearl">A 55-year-old farmer with 30 pack-years of smoking presents with dyspnea. Spirometry shows FEV1 50% predicted, FVC 75% predicted, FEV1/FVC 0.58. This ratio <0.70 immediately confirms COPD (obstructive), not restrictive disease—guiding you toward bronchodilators and smoking cessation counseling rather than immunosuppression. In India, this pattern is seen in millions with biomass-related COPD.</clinicalPearl> </invoke>